serelaxin
Jump to navigation
Jump to search
Indications
Dosage
Mechanism of action
- recombinant human relaxin-2
- vasodilator
Clinical trials
[1]
- some beneficial effect on dyspnea in selected patients
- lower 180 day mortality (7.2% vs 11.2% for placebo)
More general terms
References
- ↑ 1.0 1.1 Teerlink JR et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): A randomised, placebo- controlled trial. Lancet 2012 Nov 7 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23141816 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61855-8/fulltext
Konstam MA. RELAX-AHF: Rising from the doldrums in acute heart failure. Lancet 2012 Nov 7 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/23141815 <Internet> http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61896-0/fulltext